Related Experiment Video
Updated: Oct 1, 2026

Cholesterol Efflux Assay
Published on: March 6, 2012
[Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary
W F Riesen1, U Keller, A Del Bufalo
1Lipidlabor der Universität Bern.
Abstract:
In a Swiss multicenter study with determination of lipid and lipoprotein parameters in a central laboratory, the efficacy of simvastatin, MSD, was evaluated in patients with primary hypercholesterolemia. Lipid and lipoprotein values were determined in 109 patients before and after 6 weeks' therapy with 10 mg simvastatin per day. A significant decrease in total cholesterol, LDL-cholesterol and apo B, of 21.1, 25.8 and 24.1% respectively, was observed. No influence of simvastatin on apo A-II was found, but HDL-cholesterol and apo A-I were slightly increased (+6.1 and 4.4% respectively). The data show that HMG-CoA reductase inhibitors constitute a new class of effective drugs for the treatment of hypercholesterolemia.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Bioavailability Study Design: Single Versus Multiple Dose Studies
Bioavailability Study Design: Healthy Subjects Versus Patients
Coronary Artery Disease V: Interprofessional Care
Hypertension III: Clinical Manifestations and Diagnostic Studies
Atherosclerosis III: Management

